American Portfolios Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

American Portfolios Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$21.4K	Hold	1,700	–	–	﹤0.01%	2153
2022 Q2	$18K	Hold	1,700	–	–	﹤0.01%	2279
2022 Q1	$27.6K	Hold	1,700	–	–	﹤0.01%	2203
2021 Q4	$23.5K	Sell	1,700 -35,000	-95%	-$463K	﹤0.01%	2253
2021 Q3	$527K	Sell	36,700 -300	-0.8%	-$4.73K	0.02%	677
2021 Q2	$585K	Buy	37,000 +850	+2%	+$11.5K	0.02%	648
2021 Q1	$368K	Buy	36,150 +17,650	+95%	+$182K	0.02%	784
2020 Q4	$138K	Buy	18,500 +16,741	+952%	+$86.3K	0.01%	1028
2020 Q3	$6.04K	Buy	1,759 +759	+76%	+$3.25K	﹤0.01%	2194
2020 Q2	$4.76K	Buy	+1,000	New	+$3.99K	﹤0.01%	2262

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

American Portfolios Advisors's BCRX Position: Q3 2022 in Review

American Portfolios Advisors held its BioCryst Pharmaceuticals (BCRX) position steady in Q3 2022 at 1,700 shares worth $21.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2153.

American Portfolios Advisors first reported a position in BCRX in Q2 2020 and has held it in 10 quarters since. The position peaked at $585K in Q2 2021. 234 funds tracked by Wall St. Rank hold BCRX as of Q3 2022.

American Portfolios Advisors held 1,700 shares of BioCryst Pharmaceuticals worth $21.4K as of Q3 2022.
American Portfolios Advisors left its BioCryst Pharmaceuticals share count unchanged in Q3 2022.
BioCryst Pharmaceuticals made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #2153 holding.
American Portfolios Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2020 and has held it in 10 quarters since.
American Portfolios Advisors's BioCryst Pharmaceuticals position peaked at $585K in Q2 2021.
234 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.